Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m
Change To Partnership Comes After First Positive Pivotal Data For Blood Disorders
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.
You may also be interested in...
ARM counts $14.1bn in fundraising in the first half of 2021, up 35% from mid-year 2020. Also, Chinese mRNA players Abogen raises a $700m series C venture capital round, Pfizer prices a $1bn sustainability bond and while IPOs slow in the US, China and South Korea see new first-time offerings.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
bluebird is "shocked and disappointed" at the draft negative reimbursement decision on Zynteglo in UK but measures outlined in the NICE methods review could change fortunes of gene and cell therapies if taken forward.